Acquisition Announced

Merck & Co. acquisition of Terns Pharmaceuticals

US$6.7bn equity value

Announced 24 Mar 2026 · US$53.00 cash per share

Advisers

Terns Pharmaceuticals

Target

Financial adviser
Legal adviser
Target
Terns Pharmaceuticals
Acquirer
Merck & Co.
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.